Document Detail

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C.
MedLine Citation:
PMID:  20845506     Owner:  NLM     Status:  MEDLINE    
AIM: To analyze the efficacy and safety of a combination therapy of pegylated interferon (PEG-IFN) α-2b plus ribavirin (RBV) in older Japanese patients (65 years or older) infected with hepatitis C virus (HCV).
METHODS: This multicenter study included 938 patients with HCV genotype 1 who received 1.5 μg/kg per week PEG-IFN α-2b plus RBV 600-1000 mg/d for 48 wk and 313 HCV genotype 2 patients who received this treatment for 24 wk.
RESULTS: At 24 wk after the end of combination therapy, the overall sustained virological response (SVR) for genotypes 1 and 2 were 40.7% and 79.6%, respectively. The SVR rate decreased significantly with age in each genotype, and was markedly reduced in genotype 1 (P < 0.001). Moreover, the SVR was significantly higher in patients with genotype 1 who were less than 65 years (47.3% of 685) than in those 65 years or older (22.9% of 253) (P < 0.001) and was higher in patients with genotype 2 who were less than 65 years (82.9% of 252) than in those 65 years or older (65.6% of 61) (P = 0.004). When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV, the SVR rate significantly increased to 66.5% in patients less than 65 years and to 45.2% in those 65 years or older (P < 0.001). Adverse effects resulted in treatment discontinuation more often in patients with genotype 1 (14.4%) than in patients with genotype 2 (7.3%), especially by patients 65 years or older (24.1%).
CONCLUSION: PEG-IFN α-2b plus RBV treatment was effective in chronic hepatitis C patients 65 years or older who completed treatment with at least the minimum acceptable treatment dosage.
Mosaburo Kainuma; Norihiro Furusyo; Eiji Kajiwara; Kazuhiro Takahashi; Hideyuki Nomura; Yuichi Tanabe; Takeaki Satoh; Toshihiro Maruyama; Makoto Nakamuta; Kazuhiro Kotoh; Koichi Azuma; Junya Shimono; Shinji Shimoda; Jun Hayashi;
Related Documents :
23569516 - Coumadin-induced skin necrosis in a 64 year-old female despite lmwh bridging therapy.
17337066 - Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangi...
12692056 - Effects of alpha interferon induction plus ribavirin with or without amantadine in the ...
15270876 - Temozolomide and interferon alpha 2b in metastatic melanoma stage iv.
9692306 - Oral white sponge naevus: response to antibiotic therapy.
14693306 - Change in opioid use after the initiation of gabapentin therapy in patients with posthe...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  16     ISSN:  2219-2840     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-16     Completed Date:  2011-01-28     Revised Date:  2014-05-20    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  4400-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Hepacivirus / genetics
Hepatitis C, Chronic / drug therapy*
Interferon-alpha / therapeutic use*
Liver / pathology,  virology
Middle Aged
Polyethylene Glycols / therapeutic use*
Recombinant Proteins
Ribavirin / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2b; 49717AWG6K/Ribavirin; 99210-65-8/interferon alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic ...
Next Document:  Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.